Table 2.
Demographics and comparison of elective neurosurgical oncology cases between 2019 and 2020
| Elective admissions | 2020 | 2019 |
|---|---|---|
| n = 32 | n = 59 | |
| Gender | ||
| Male | 15 (46.9%) | 31 (52.5%) |
| Female | 17 (53.1%) | 28 (47.5%) |
| Mean Age (years) | 50.5 | 46 |
| Mean time from admission to surgery (days) | 2.2 (1.7–2.9) | 1.2 (1.07–1.41) |
| Glial tumours | 10 (31.25%) | 17 (28.8%) |
| Pilocytic astrocytoma | – | 1 (5.9%) |
| Astrocytoma, WHO 2 | 2 (20%) | 6 (35.3%) |
| Oligodendroglioma, WHO 2 | 1 (10%) | – |
| Astrocytoma, WHO 3 | 4 (40%) | 1 (5.9%) |
| Astroblastoma | – | 1 (5.9%) |
| GBM | 3 (30%) | 8 (47%) |
| Non-glial tumours | 22 (68.75%) | 42 (71.2%) |
| Pituitary tumours | 0 | 9 (21.43%) |
| Metastatic tumours | 4 (18.18%) | 3 (7.14%) |
| Others* | 18 (81.82%) | 30(71.43%) |
DNET dysembryoplastic neuroepithelial tumour, GBM glioblastoma multiforme,
KPI key performance index, WHO World Health Organization
*Includes colloid cyst, dysembryoplastic neuroepithelial tumour, lymphoma, germioma, ependymoma, myxopapillary Ependymoma, haemangioblastoma, meningioma, schwannoma, endo-dermal cyst and chondrosarcoma